Seth Klarman: portfolio of Baupost Group
Seth Klarman leads the Baupost Group, which follows a value approach and looks for securities trading below their estimated worth.
Source: 13F filing with the US Securities and Exchange Commission dated Feb 14, 2017. It shows positions at quarter end and is filed up to 45 days later – today the positions may be several months old. It covers only securities traded on US exchanges, without short positions; securities traded only abroad and cash are not included. Form 13F filingInvestment managers with discretion over at least 100 million USD in reportable US securities (mainly stocks and ETFs, plus options and convertible bonds) report their holdings to the SEC within 45 days after each quarter. Short positions, securities traded only abroad and cash are not included.Example: Positions as of 30 Sep, filed on 14 Nov → they are already six weeks old when published.More in the Academy: Glossary
You are looking at Q4 2016. Go to the latest filing (Q3 2026)
- Total value of stock positions
- 7.6B USD
- Positions
- 42
- Share of the ten largest
- 72.4%
The ten largest positions Q4 2016
- Cheniere Energy Inc 11.8%▼ −22.0%
- Viasat Inc 11.5%▲ +14.1%
- Synchrony Financial 9.9%▲ +17.6%
- Allergan PLC 9.5%▲ +71.5%
- Twenty First Centy Fox Inc 7.1%▲ +50.1%
- Pbf Energy Inc 5.8%unchanged
- Dell Technologies 4.8%unchanged
- Antero Res Corp 4.5%unchanged
- Theravance Biopharma Inc 3.9%▲ +26.2%
- Northstar Asset Mgmt Group I 3.7%▲ +88.7%
Show all positions of this quarter
Choose a quarter (54 filings)
- Q3 2026
- Q2 2026
- Q1 2026
- Q4 2025
- Q3 2025
- Q2 2025
- Q1 2025
- Q4 2024
- Q3 2024
- Q2 2024
- Q1 2024
- Q4 2023
- Q3 2023
- Q2 2023
- Q1 2023
- Q4 2022
- Q3 2022
- Q2 2022
- Q1 2022
- Q4 2021
- Q3 2021
- Q2 2021
- Q1 2021
- Q4 2020
- Q3 2020
- Q2 2020
- Q1 2020
- Q4 2019
- Q3 2019
- Q2 2019
- Q1 2019
- Q4 2018
- Q3 2018
- Q2 2018
- Q1 2018
- Q4 2017
- Q3 2017
- Q2 2017
- Q1 2017
- Q4 2016
- Q3 2016
- Q2 2016
- Q1 2016
- Q4 2015
- Q3 2015
- Q2 2015
- Q1 2015
- Q4 2014
- Q3 2014
- Q2 2014
- Q1 2014
- Q4 2013
- Q3 2013
- Q2 2013
All positions Q4 2016
| Symbol | Weight | Shares | Reported value | Change | Held since |
|---|---|---|---|---|---|
| Cheniere Energy Inc | 11.8% | 21,726,340 | 900.1M USD | −22.0% reduced | Q1 2014 12 quarters |
| Viasat Inc | 11.5% | 13,158,137 | 871.3M USD | +14.1% increased | Q2 2013 or earlier 15 quarters |
| SYF Synchrony Financial | 9.9% | 20,665,000 | 749.5M USD | +17.6% increased | Q3 2016 2 quarters |
| Allergan PLC | 9.5% | 3,432,603 | 720.9M USD | +71.5% increased | Q1 2016 4 quarters |
| Twenty First Centy Fox Inc | 7.1% | 19,137,469 | 536.6M USD | +50.1% increased | Q3 2015 6 quarters |
| Pbf Energy Inc | 5.8% | 15,724,175 | 438.4M USD | unchanged | Q3 2013 14 quarters |
| DELL Dell Technologies | 4.8% | 6,652,459 | 365.7M USD | unchanged | Q3 2016 2 quarters |
| Antero Res Corp | 4.5% | 14,505,881 | 343.1M USD | unchanged | Q3 2014 10 quarters |
| Theravance Biopharma Inc | 3.9% | 9,273,991 | 295.7M USD | +26.2% increased | Q2 2014 11 quarters |
| Northstar Asset Mgmt Group I | 3.7% | 18,705,000 | 279.1M USD | +88.7% increased | Q3 2016 2 quarters |
| Northstar Rlty Fin Corp | 2.9% | 14,577,134 | 220.8M USD | +165.1% increased | Q3 2016 2 quarters |
| Twenty First Centy Fox Inc | 2.6% | 7,278,100 | 198.3M USD | unchanged | Q3 2015 6 quarters |
| Veritiv Corp | 2.2% | 3,044,385 | 163.6M USD | unchanged | Q3 2014 10 quarters |
| Innoviva Inc | 2.1% | 14,931,483 | 159.8M USD | unchanged | Q1 2016 4 quarters |
| Keryx Biopharmaceuticals Inc | 2.0% | 25,791,678 | 151.1M USD | unchanged | Q1 2014 12 quarters |
| Colony Cap Inc | 1.9% | 6,959,017 | 140.9M USD | +56.5% increased | Q3 2016 2 quarters |
| MCK McKesson Corporation | 1.8% | 1,000,000 | 140.5M USD | new | Q4 2016 1 quarter |
| Forward Pharma A/S | 1.1% | 5,367,300 | 80.5M USD | unchanged | Q4 2014 9 quarters |
| Atara Biotherapeutics Inc | 1.0% | 5,359,632 | 76.1M USD | unchanged | Q4 2014 9 quarters |
| CAH Cardinal Health | 1.0% | 1,030,000 | 74.1M USD | new | Q4 2016 1 quarter |
| Liberty Media Corp Delaware | 0.8% | 2,994,010 | 61.6M USD | unchanged | Q2 2016 3 quarters |
| American Intl Group Inc | 0.8% | 2,594,317 | 60.9M USD | unchanged | Q2 2013 or earlier 15 quarters |
| Syngenta AG | 0.8% | 745,136 | 58.9M USD | new | Q4 2016 1 quarter |
| Liberty Interactive Corp | 0.7% | 1,481,719 | 54.6M USD | new | Q4 2016 1 quarter |
| Credit Accep Corp Mich | 0.7% | 244,400 | 53.2M USD | +144.4% increased | Q2 2016 3 quarters |
| Chipmos Technologies Inc | 0.7% | 3,509,858 | 49.5M USD | new | Q4 2016 1 quarter |
| Gty Technology Holdings Inc | 0.6% | 4,400,000 | 46.2M USD | new | Q4 2016 1 quarter |
| Centennial Resource Dev Inc | 0.6% | 2,407,153 | 43.6M USD | new | Q4 2016 1 quarter |
| Novagold Res Inc | 0.6% | 9,500,000 | 43.3M USD | unchanged | Q2 2013 or earlier 15 quarters |
| COR Cencora | 0.5% | 502,474 | 39.3M USD | new | Q4 2016 1 quarter |
| Conyers Pk Acquisition | 0.5% | 3,712,500 | 38.0M USD | unchanged | Q3 2016 2 quarters |
| Paratek Pharmaceuticals Inc | 0.4% | 2,044,498 | 31.5M USD | unchanged | Q4 2014 9 quarters |
| Saban Cap Acquisition Corp | 0.3% | 2,326,500 | 23.3M USD | new | Q4 2016 1 quarter |
| Cascadian Therapeutics Inc | 0.2% | 4,166,666 | 18.0M USD | new | Q4 2016 1 quarter |
| Liberty Media Corp Delaware | 0.2% | 800,000 | 16.4M USD | unchanged | Q2 2016 3 quarters |
| Liberty Expedia Holdings | 0.2% | 395,613 | 15.7M USD | new | Q4 2016 1 quarter |
| RUN Sunrun | 0.2% | 2,848,082 | 15.1M USD | unchanged | Q3 2015 6 quarters |
| Citigroup Inc | 0.1% | 62,903,207 | 9.6M USD | −38.7% reduced | Q2 2013 or earlier 15 quarters |
| Trilogy Metals Inc New | < 0.1% | 10,600,758 | 5.3M USD | unchanged | Q3 2016 2 quarters |
| Orexigen Therapeutics Inc | < 0.1% | 2,226,839 | 3.9M USD | unchanged | Q3 2016 2 quarters |
| Conyers Pk Acquisition | < 0.1% | 1,237,500 | 2.5M USD | unchanged | Q3 2016 2 quarters |
| Saban Cap Acquisition Corp | < 0.1% | 1,163,250 | 1.1M USD | new | Q4 2016 1 quarter |
“Held since”: the first quarter from which the position appears in the 13F filing at every quarter end. It first appears at the end of that quarter – the filing gives neither date nor price, and trading between two quarter ends is not visible. “Or earlier”: the position was already in the first available filing (or the first one after a gap in filings). After a change of the security identifier (e.g. a renaming) the start may appear later.
Plus 2 positions in convertible bonds and bonds worth 72.4M USD as reported – not included in the weights.
Convertible bonds and bonds, principal amount as reported. They are not stock positions and therefore do not count towards the weights.
- Theravance Inc principal 46.2M USD 38.4M USD
- Theravance Biopharma Inc principal 30.0M USD 34.1M USD
Breakdown by sector
- Financials 9.9%
- Technology 4.8%
- Health Care 3.3%
- Industrials 0.2%
- not in our coverage 81.8%
Sectors only for stocks we cover; the rest is grouped under “not in our coverage”.
How to read this page
- Weight: a position’s share of the total value of all reported stock positions in this quarter – options and bonds are not counted.
- Change: number of shares compared with the previous quarter. After a stock split we convert the previous quarter’s share count so that a split does not look like an increase; if a possible split cannot be confirmed, “–” is shown.
- Reported value: value of the position at quarter end as reported by the investor. The portfolio may have changed since then.
All superinvestor portfolios Screener: stocks held by superinvestors